Bavi demonstrated doubling of survival in second-line NSCLC. PPHM is running the confirmatory phase3 trial now at over 150 clinical sites, worldwide.
Studies show that anti-PS can be combined safely and efficaciously with multiple agents, such as, chemotherapies, irradiation, and other mAbs, including the emerging downstream immunotherapies.
Peregrine has confirmed that they are already in multiple, “dozens”, collaborations with Bavi. That is a strong signal to investors of the interest of other entities in the anti-PS platform.
Just recently CEO King made the following comment in a prepared statement.
“Bavi has the potential to be combined with many other treatments that are already the Standard of Care.” (SOC)
That is a very interesting strategy!
Bavituximab is a well proven safe and efficacious immunotherapy that can be combined with many, above mentioned, categories of medicines. If the medicine is already the SOC for a particular cancer indication, then Peregrine, or possibly its acquirer, could run bavi with multiple SOCs to tag on and become part of that SOC treatment.
Yervoy, anti-CTLA-4, is currently the Standard of Care for treatment of advanced melanoma.
So, Peregrine has already started the process of going after the immunotherapy Standard of Care with its Yervoy + Bavi trial in advanced melanoma. A phase1b open label, this trial should show us some interesting response rate data this year. Dr. Rolf Brekken has stated that Bavi can increase response rates by 200% to 300% when combined with other immunotherapies. Nicely enhanced response rates are what we will look for in the melanoma trial of Bavi with Yervoy.
Bavi offers super synergy when combined with many other medicines, along with a great safety record after treating many hundreds of patients.
Bavi is a broad-spectrum medicine with a universal target, (PS), that co-locates with diseases like cancer. There are many cancer indications that are still challenged by a lack of safe and efficacious treatments with their current standard of care.
I believe the Peregrine strategy to go after multiple Standards of Care by adding anti-PS, Bavi immunotherapy is brilliant, and will accelerate the growth of the company. Astronomical comes to mind!
Below is a short list of cancers that could benefit from a universal immunotherapy boost. Dr. Axel Hoos touted the promise of immunotherapy combinations, and we will certainly be seeing them. In fact, Peregrine already has one going in melanoma.
IMO
sunstar
A
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia
Adrenocortical carcinoma
AIDS-related cancers
AIDS-related lymphoma
Anal cancer
Appendix cancer
Astrocytoma, childhood cerebellar or cerebral
B
Basal-cell carcinoma
Bile duct cancer, extrahepatic (see Cholangiocarcinoma)
Bladder cancer
Bone tumor, Osteosarcoma/Malignant fibrous histiocytoma
Brainstem glioma
Brain cancer
Brain tumor, cerebellar astrocytoma
Brain tumor, cerebral astrocytoma/malignant glioma
Brain tumor, ependymoma
Brain tumor, medulloblastoma
Brain tumor, supratentorial primitive neuroectodermal tumors
Brain tumor, visual pathway and hypothalamic glioma
Breast cancer
Bronchial adenomas/carcinoids
Burkitt's lymphoma
C
Carcinoid tumor, childhood
Carcinoid tumor, gastrointestinal
Carcinoma of unknown primary
Central nervous system lymphoma, primary
Cerebellar astrocytoma, childhood
Cerebral astrocytoma/Malignant glioma, childhood
Cervical cancer
Childhood cancers
Chronic bronchitis
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Chronic myeloproliferative disorders
Chronic obstructive pulmonary disease (COPD)
Colon Cancer
Cutaneous T-cell lymphoma
D
Desmoplastic small round cell tumor
E
Emphysema
Endometrial cancer
Ependymoma
Esophageal cancer
Ewing's sarcoma in the Ewing family of tumors
Extracranial germ cell tumor, Childhood
Extragonadal Germ cell tumor
Extrahepatic bile duct cancer
Eye Cancer, Intraocular melanoma
Eye Cancer, Retinoblastoma
G
Gallbladder cancer
Gastric (Stomach) cancer
Gastrointestinal Carcinoid Tumor
Gastrointestinal stromal tumor (GIST)
Germ cell tumor: extracranial, extragonadal, or ovarian
Gestational trophoblastic tumor
Glioma of the brain stem
Glioma, Childhood Cerebral Astrocytoma
Glioma, Childhood Visual Pathway and Hypothalamic
Gastric carcinoid
H
Hairy cell leukemia
Head and neck cancer
Heart cancer
Hepatocellular (liver) cancer
Hodgkin lymphoma
Hypopharyngeal cancer
Hypothalamic and visual pathway glioma, childhood
I
Intraocular Melanoma
Islet Cell Carcinoma (Endocrine Pancreas)
K
Kaposi sarcoma
Kidney cancer (renal cell cancer)
L
Laryngeal Cancer
Leukemias
Leukemia, acute lymphoblastic (also called acute lymphocytic leukemia)
Leukemia, acute myeloid (also called acute myelogenous leukemia)
Leukemia, chronic lymphocytic (also called chronic lymphocytic leukemia)
Leukemia, chronic myelogenous (also called chronic myeloid leukemia)
Leukemia, hairy cell
Lip and Oral Cavity Cancer
Liposarcoma
Liver Cancer (Primary)
Lung Cancer, Non-Small Cell
Lung Cancer, Small Cell
Lymphomas
Lymphoma, AIDS-related
Lymphoma, Burkitt
Lymphoma, cutaneous T-Cell
Lymphoma, Hodgkin
Lymphomas, Non-Hodgkin (an old classification of all lymphomas except Hodgkin's)
Lymphoma, Primary Central Nervous System
M
Macroglobulinemia, Waldenström
Male breast cancer
Malignant Fibrous Histiocytoma of Bone/Osteosarcoma
Medulloblastoma, Childhood
Melanoma
Melanoma, Intraocular (Eye)
Merkel Cell Carcinoma
Mesothelioma, Adult Malignant
Mesothelioma, Childhood
Metastatic Squamous Neck Cancer with Occult Primary
Mouth Cancer
Multiple Endocrine Neoplasia Syndrome, Childhood
Multiple Myeloma/Plasma Cell Neoplasm
Mycosis Fungoides
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Myelogenous Leukemia, Chronic
Myeloid Leukemia, Adult Acute
Myeloid Leukemia, Childhood Acute
Myeloma, Multiple (Cancer of the Bone-Marrow)
Myeloproliferative Disorders, Chronic
N
Nasal cavity and paranasal sinus cancer
Nasopharyngeal carcinoma
Neuroblastoma
Non-Hodgkin lymphoma
Non-small cell lung cancer
O
Oral Cancer
Oropharyngeal cancer
Osteosarcoma/malignant fibrous histiocytoma of bone
Ovarian cancer
Ovarian epithelial cancer (Surface epithelial-stromal tumor)
Ovarian germ cell tumor
Ovarian low malignant potential tumor
P
Pancreatic cancer
Pancreatic cancer, islet cell
Paranasal sinus and nasal cavity cancer
Parathyroid cancer
Penile cancer
Pharyngeal cancer
Pheochromocytoma
Pineal astrocytoma
Pineal germinoma
Pineoblastoma and supratentorial primitive neuroectodermal tumors, childhood
Pituitary adenoma
Plasma cell neoplasia/Multiple myeloma
Pleuropulmonary blastoma
Primary central nervous system lymphoma
Prostate cancer
R
Rectal cancer
Renal cell carcinoma (kidney cancer)
Renal pelvis and ureter, transitional cell cancer
Retinoblastoma
Rhabdomyosarcoma, childhood
S
Salivary gland cancer
Sarcoma, Ewing family of tumors
Sarcoma, Kaposi
Sarcoma, soft tissue
Sarcoma, uterine
Sézary syndrome
Skin cancer (nonmelanoma)
Skin cancer (melanoma)
Skin carcinoma, Merkel cell
Small cell lung cancer
Small intestine cancer
Soft tissue sarcoma
Squamous cell carcinoma – see Skin cancer (nonmelanoma)
Squamous neck cancer with occult primary, metastatic
Stomach cancer
Supratentorial primitive neuroectodermal tumor, childhood
T
T-Cell lymphoma, cutaneous – see Mycosis Fungoides and Sézary syndrome
Testicular cancer
Throat cancer
Thymoma, childhood
Thymoma and Thymic carcinoma
Thyroid cancer
Thyroid cancer, childhood
Transitional cell cancer of the renal pelvis and ureter
Trophoblastic tumor, gestational
U
Unknown primary site, carcinoma of, adult
Unknown primary site, cancer of, childhood
Ureter and renal pelvis, transitional cell cancer
Urethral cancer
Uterine cancer, endometrial
Uterine sarcoma
V
Vaginal cancer
Visual pathway and hypothalamic glioma, childhood
Vulvar cancer
W
Waldenström macroglobulinemia
Wilms tumor (kidney cancer), childhood
AI
